Shares of Indaptus Therapeutics, Inc. [NASDAQ: INDP] skyrocketed 172% at the time of writing on Wednesday. The strong performance of the firm came after it has disclosed that the United States Patent and Trademark Office has awarded a notice of allowance for claims related to the firm’s platform technology.
It has been disclosed that the patent, named, “Methods of Treatment of Infections Using Bacteria,” offers broad protection for the application of the firm’s platform technology alone and in combination with standards of care for the cure and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
Furthermore, this notice of allowance provides the firm the choice to positively continue its technology in viral diseases and/or to collaborate with it for further development. INDP stated that it is thrilled to increase its growing patent estate and this notice of allowance offers additional validation of the novel approach of its Indaptus platform technology as it relates to viral infections.
Additionally, the Indaptus pipeline is entrenched in the hypothesis that highly efficient anti-tumor or anti-viral immunotherapy will need safe activation of both innate and adaptive immunity in both tumors and sites of infection, as well as immune organs. It has been disclosed that this might be accomplished with a multi-targeted package of bacterial immune system activators, in the form of attenuated, killed, and intact, non-pathogenic bacteria sent intravenously.